Sign in Subscribe
Cancer

HER2+ Gastric Cancer Market to Witness Significant Growth in the 7MM

Strategic Insights

— 2 min read

DelveInsight's HER2+ Gastric Cancer Market report provides a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ gastric cancer market size from 2020 to 2034, segmented into 7MM (the United States, the EU4, the United Kingdom, and Japan).

As per DelveInsight's analysis, the total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025-2034). The total number of incident cases of HER2+ gastric cancer in the 7MM accounted for approximately 45,000 in 2024, expected to increase by 2034.

Key Takeaways:

  • The largest revenue-generating therapy for HER2+ gastric cancer in the US in 2024 was Trastuzumab +- Chemotherapy, with a revenue of approximately USD 140 million.
  • Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) is the only approved therapy for the treatment of advanced or metastatic HER2+ gastric cancer for 2L therapy, receiving accelerated approval in January 2021.
  • ENHERTU (trastuzumab deruxtecan) is expanding into the first-line treatment setting, which is expected to increase its patient share and drive growth in the market size.
  • Emerging therapies in the pipeline include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
  • Data presented during the recent ASCO 2025 meeting showed that ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJ following progression on first-line therapy.
  • AstraZeneca anticipated a data readout from the Phase Ib/II trial (NCT04379596, DESTINY-Gastric03) in 2026, focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA.
  • Jazz Pharmaceuticals anticipated the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026.

Statistics:

  • Total market size of HER2+ gastric cancer (including GEJ) in the 7MM: approximately USD 700 million in 2024.
  • Incident cases of HER2+ gastric cancer in the 7MM: approximately 45,000 in 2024, expected to increase by 2034.
  • Revenue generated by Trastuzumab +- Chemotherapy in the US in 2024: approximately USD 140 million.
  • Phase III DESTINY-Gastric04 trial: ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJ following progression on first-line therapy.
  • Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial: expected to begin patient dosing in Q1 2025, with data anticipated to be available after 2026.

Sources:

  • DelveInsight Business Research, LLP
  • AstraZeneca
  • Daiichi Sankyo
  • Jazz Pharmaceuticals
  • ASCO 2025 meeting
  • NCT04379596 (DESTINY-Gastric03) trial
  • NCT06731478 (DESTINY-Gastric05) trial

Read more